2004
Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors
Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors. Clinical Cancer Research 2004, 10: 2968-2976. PMID: 15131032, DOI: 10.1158/1078-0432.ccr-03-0412.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerGrade 4 diarrheaCell lung cancerPartial responseLung cancerMetastatic non-small cell lung cancerSolid tumorsGrade 3 peripheral neuropathyPrincipal grade 3/4 toxicitiesDose level 3Durable partial responseGrade 3 hyperbilirubinemiaPrevious taxane therapyGrade 3/4 toxicitiesGrade 4 neutropeniaPhase II trialDose-limiting toxicityPhase I trialFarnesyltransferase inhibitor lonafarnibNovel farnesyltransferase inhibitorPlasma paclitaxelII trialTaxane therapyCombination regimenMedian duration
1997
Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
Strauss G, Lynch T, Elias A, Jacobs C, Herbst R, Leong T, Lynch C, Kwiatkowski D, Carey R, Grossbard M, Skarin A. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis. Seminars In Oncology 1997, 24: s12-73-s12-80. PMID: 9331127.Peer-Reviewed Original ResearchConceptsAdvanced lung cancerIfosfamide/carboplatin/etoposide chemotherapyCarboplatin/etoposide chemotherapySmall cell carcinomaCell carcinomaLung cancerResponse rateStage IIIAEtoposide chemotherapyMedian survivalGranulocyte colony-stimulating factor supportNon-small cell lung cancerColony-stimulating factor supportPreliminary survival analysisSingle-agent paclitaxelGrade 4 neutropeniaGrade 4 thrombocytopeniaLarge cell carcinomaCell lung cancerSquamous cell carcinomaGranulocyte colony-stimulating factorColony-stimulating factorNonhematologic toxicityPredominant toxicityHematologic toxicity